Human TRAIL R1/DR4/TNFRSF10A Protein
Catalog No: DR4-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human TRAIL R1/DR4/TNFRSF10A Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Ala24-Asn239 (UniProt accession: O00220).
Product Details
- Molecular Aliases
- DR4; CD261; TNFRSF10A; TRAIL-R; APO2; TRAIL R1; MGC9365
- Protein Length
- Ala24-Asn239
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 48.8 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human TRAIL R1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human TRAIL R1 is greater than 95% as determined by SEC-HPLC.
Immobilized Human TRAIL, No Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 11.1ng/ml determined by ELISA.
Background
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.
References
- Deng D, Shah K. TRAIL of Hope Meeting Resistance in Cancer. Trends Cancer. 2020 Dec;6(12):989-1001. doi: 10.1016/j.trecan.2020.06.006. Epub 2020 Jul
- PMID: 32718904; PMCID: PMC7688478. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.